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Introduction: A barrier to preventative treatments for psy-
chosis is the absence of accurate identification of persons at 
highest risk. A blood test that could substantially increase 
diagnostic accuracy would enhance development of psycho-
sis prevention interventions. Methods: The North American 
Prodrome Longitudinal Study project is a multisite endeavor 
that aims to better understand predictors and mechanisms 
for the development of psychosis. In this study, we measured 
expression of plasma analytes reflecting inflammation, oxi-
dative stress, hormones, and metabolism. A “greedy algo-
rithm” selected analytes that best distinguished persons 
with clinical high-risk symptoms who developed psychosis 
(CHR-P; n = 32) from unaffected comparison (UC) sub-
jects (n = 35) and from those who did not develop psychosis 
during a 2-year follow-up (CHR-NP; n = 40). Results: The 
classifier included 15 analytes (selected from 117), with an 
area under the receiver operating curve for CHR-P vs UC 
of 0.91 and CHR-P vs CHR-NP of 0.88. Randomly scram-
bled group membership followed by reconstructions of the 
entire classifier method yielded consistently weak classifi-
ers, indicating that the true classifier is highly unlikely to be 
a chance occurrence. Such randomization methods robustly 
imply the assays contain consistent information distinguish-
ing the groups which was not obscured by the data normal-
ization method and was revealed by classifier construction. 
These results support the hypothesis that inflammation, oxi-
dative stress, and dysregulation of hypothalamic-pituitary 
axes may be prominent in the earliest stages of psychosis. 
Conclusion: If confirmed in other groups of persons at 
elevated risk of psychosis, a multiplex blood assay has the 
potential for high clinical utility.
Key words: clinical high risk/psychosis/prodrome/ 
multiplex/risk prediction/malondialdehyde-modified 
low-density lipoprotein (MDA-LDL)/immune/ 
inflammation/oxidative stress
Introduction
It is well established that early intervention is associated 
with better clinical outcomes in persons with schizo-
phrenia,1 raising the hope that treatment during the pro-
dromal phase of illness could prevent the development 
of a psychotic disorder and thus reduce risk of chronic 
symptoms and disability. Substantial progress has been 
made in establishing clinical criteria to identify persons 
at high risk (CHR) for psychosis, with about 20%–25% 
developing psychosis within a year and 30%–35% within 
2 years.2–4 An “attenuated psychosis syndrome” was con-
sidered for inclusion in the most recent Diagnostic and 
Statistical Manual, Fifth Edition (DSM-5).5 However, 
the expert panel decided to place the syndrome in the 
DSM-5 Appendix due to concerns that specificity would 
be low and that a minority of persons meeting syndrome 
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criteria would actually progress to develop a psychotic 
disorder.6,7 This decision reinforces the need for further 
research to identify biological validators of a high-risk 
state for psychosis warranting preventative interventions.
In general, biomarker tests are most useful for persons 
at elevated risk for a disease because the proportion of 
patients who test positive and who actually get the disease 
(positive predictive value, PPV) varies dramatically depend-
ing on the actual rate of disease in the tested population.8 
If the rate of disease is low, eg, if 1% of tested persons are 
actually at risk, then even a test with high sensitivity and 
specificity (~0.80) will have 20 times as many false posi-
tives as true positive (supplement S1). To minimize the risk 
of embarking on an inappropriate treatment program, any 
biomarker test with less than perfect specificity needs be 
applied in a relatively high-risk population. Applied to per-
sons meeting CHR criteria, a biomarker test with reason-
able sensitivity and specificity (~0.8) can achieve a PPV of 
about 0.63; equivalently, about two-thirds of persons iden-
tified by such a test as at risk would truly be on a trajec-
tory to develop psychosis. Of, perhaps, equal significance is 
that such a diagnostic test could have a negative predictive 
power of about 0.90, increasing a clinician’s confidence in 
predicting who is likely not to develop psychosis.
Patients with schizophrenia are reported to have anom-
alous levels of markers of inflammation, oxidative stress, 
metabolism, and hormonal status.9–15 For this reason, we 
investigated whether plasma analytes representing these 
components could be used to construct a classifier that 
distinguishes persons with CHR risk symptoms who 
developed psychosis from persons with CHR symptoms 
who did not develop psychosis during a 2-year follow-up 
period, as well as from unaffected comparison subjects.
Methods
Subjects
The aims and methods of North American Prodrome 
Longitudinal Study (NAPLS 2) were described in detail 
previously.16 To summarize, NAPLS 2 is an 8-site obser-
vational study of the predictors and mechanisms of 
conversion to psychosis in persons meeting the Criteria 
of Prodromal States (COPS).17 The NAPLS 2 cohort 
includes 765 clinical high-risk and 280 demographi-
cally similar unaffected comparison (UC) subjects aged 
between 12 and 35. The study was approved by the 
Institutional Review Board at each site, and each subject 
provided written informed consent or assent, with a par-
ent or guardian also consenting for minor subjects.
The plasma analysis reported here was conducted in 
March 2012. We included all CHR subjects with plasma 
samples either who had progressed to psychosis (CHR-P, n 
= 32) or who had been followed 2 years and not progressed 
to psychosis (CHR-NP, n = 40) as of February 2012. Note 
that because this is a nested case-control study conducted 
before completion of study follow-up, no inference can me 
made about conversion rates in this report. The unaffected 
comparison subjects (UC, n = 35) did not meet CHR cri-
teria or have a history of a psychotic disorder and were 
chosen to be demographically similar to the CHR subjects.
Assessments
Clinical assessments were done every 6 months and sub-
jects followed for up to 2 years. Participants were screened 
using the Structured Interview for Prodromal Syndromes 
(SIPS) and rated with the Scale of Prodromal Symptoms 
(SOPS) for the presence of one or more prodromal syn-
dromes: attenuated psychotic symptoms, brief  intermit-
tent psychotic symptoms, substantial functional decline 
combined with a first-degree relative with a psychotic 
disorder, or schizotypal personality disorder in individu-
als younger than 18 years.17 Details regarding the SIPS, 
SOPS, and COPS are included in supplementary meth-
ods. The Structured Clinical Interview for DSM IV18 was 
used to determine psychiatric diagnoses.
Depressive symptoms were evaluated with the Calgary 
Depression Scale for Schizophrenia19 (CDSS) and anxi-
ety symptoms with the Self-Rated Anxiety Scale20 (SAS). 
Data on prescription medications were based on self-
reports. Socioeconomic status was estimated by maxi-
mum years of education of mother or father. Substance 
use was evaluated with the Alcohol/Drug Use Scales21 as 
a dichotomous variable, and by frequency of use (0 = no 
use, 5 = daily use, or for cigarettes > 25 per day).
Plasma Collection
Blood samples used in this analysis were drawn at the 
baseline visit in Becton Dickenson P100 blood collection 
tubes with ethylene diamine tetra-acetic acid as antico-
agulant, proprietary protein stabilizers, and a mechanical 
separator. All samples were processed within 120 minutes 
(mean time to freezer = 28 minutes, SD = 2 minutes) and 
stored at −80°C until analysis.
Plasma Assay
Plasma samples were sent on dry ice to Myriad Rules 
Based Medicine, a biomarker testing laboratory that has 
maintained clinical laboratory improvement amendments-
accreditation by the Commission on Office Laboratory 
Accreditation since 2006. Samples were analyzed with the 
Human Discovery Map assay, a Luminex bead-based mul-
tiplex immunoassay that included 185 analytes involved 
in hormonal responses, inflammation, growth, oxida-
tive stress, and metabolism, all according to Rules-Based 
Medicine standard operating procedures. Technicians ran 
assays without knowledge of clinical status of the subjects.
Exclusion of Analytes
The assay included185 analytes. We excluded 23 analytes 
that were not detected in ≥ 20% of the subjects. Most 
421
Towards a Psychosis Risk Blood Diagnostic
remaining analytes (80%) were detected in at least 90% of 
the 107 subjects (supplement S2).
Persons exhibiting CHR symptoms are often pre-
scribed various medications by their health care pro-
vider,22,23 and in our CHR subjects, 19% were prescribed 
antipsychotics and 28% were prescribed antidepressants 
(table 1). In addition CHR subjects were more likely to use 
marijuana and nicotine, compared with UC subjects, and 
alcohol use occurred in almost half  of subjects (table 1). 
Antipsychotics, antidepressants, marijuana, nicotine, and 
alcohol may impact inflammation, oxidative stress, and 
hormonal pathways,10,15,24–31 raising the possibility that 
drug use could confound differences in analyte expres-
sion comparisons between groups. To minimize risk of 
confounding, we excluded analytes with a possible rela-
tion to prescription of antipsychotics or antidepressants, 
or with self-reported current use of marijuana, nicotine, 
or alcohol, based on comparisons of analyte expression 
levels between persons using vs not using the substance. 
Consequently, 45 additional analytes were excluded 
Table 1. Demographic and Clinical Characteristics of Study Subjects
Unaffected  
Comparison  
(UC) N = 35
Clinical High Risk,  
Not Psychotic  
(CHR-NP) N = 40
Clinical High 
Risk, Psychotic 
(CHR-P) N = 32
Age, average (SD) 20 (4.5) 19.5 (4.6) 19.2 (3.7)
Ancestry
 Caucasian, % 60 65 55
 African, % 31 17.5 21
 Asian, % 9 17.5 24
Sex, female, % 34 37.5 30.3
Socioeconomic status, average (SD) 4.8 (1.8) 4.5 (2.3) 4.5 (1.8)
Scale of Prodromal Symptom scores, average (SD)
 Totala 5.06 (5.11) 36.63 (13.03) 43.81 (14.11)
 Positivea 1.46 (1.84) 12.28 (4.74) 14.22 (3.92)
 Negativea 1.23 (1.72) 11.38 (6.32) 13.58 (6.23)
 Disorganizeda 0.91 (1.17) 5.05 (2.79) 6.45 (3.88)
 Generala,b 1.46 (1.80) 7.93 (4.46) 10.52 (4.44)
Calgary Depression Scale for Schizophrenia  
scores,a average (SD)
0.89 (1.71) 5.00 (4.72) 6.88 (4.88)
Zung Self-Rated Anxiety Scale,a average (SD) 28.79 (4.15) 45.80 (13.35) 48.39 (12.55)
Time blood draw, average (SD) 12:12 pm (1.85 h) 12:39 pm (2.0 h) 11:59 am (1.79 h)
Prescription medication
 Antipsychoticc 0% 25% 13%
 Antidepressantd 1% 30% 25%
 Stimulant 0% 8% 6%
 Mood stabilizer 0% 5% 3%
 Benzodiazepinee 0% 5% 13%
 Nonsteroidal anti-inflammatory drug 0% 0% 0%
 Antibiotic 0% 0% 0%
Substance use
 Tobacco usef 9% 30% 44%
 Alcohol use 46% 48% 38%
 Marijuana useg 9% 25% 31%
Current comorbid Diagnostic and Statistical  
Manual of Mental Disorders IV diagnosis
 Depression disordersh,i 0% 45% 50%
 Anxiety disordersi,j 3% 60% 56%
aCHR-P vs UC t test P value < .0001, CHR-NP vs UC t test P value < .0001.
bCHR-P vs CHR-NP t test P value = .02.
cCHR-P vs UC Fisher Exact Test (FET) P value = .047, CHR-NP vs UC FET P value = .001.
dCHR-P vs UC FET P value = .011, CHR-NP vs UC FET P value = .002.
eCHR-P vs UC FET P value = .047.
fCHR-P vs UC FET P value = .001, CHR-NP vs UC FET P value = .02.
gCHR-P vs UC FET P value = .020, CHR-NP vs UC FET P value = .056.
hCHR-P vs UC FET P value < .0001, CHR-NP vs UC FET P value < .0001.
iDepression disorders include major depression, depressive disorder not otherwise specified, and dysthymic disorder. Anxiety disorders 
include obsessive compulsive disorder, post-traumatic stress disorder, panic disorder, agoraphobia, social phobia, specific phobia, and 
generalized anxiety disorder.
jCHR-P vs UC FET P value < .0001, CHR-NP vs UC FET P value < .0001.
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(supplement S2). We conducted further analyses in the 
remaining 117 analytes.
Normalization
The normal plasma concentrations varied analyte-to-
analyte up to 1  000  000-fold. So that results could be 
viewed on the same scale, we standardized (z score) the 
results for each analyte to the average and SD values of 
the unaffected comparison subjects.
Reproducibility
We had resources to analyze one technical replicate. The 
intraclass correlation coefficient (ICC) of the 117 analyte 
levels for the duplicate samples was 0.83; for the 15 ana-
lytes selected by the greedy algorithm described below, 
the ICC was 0.87 (supplement S3).
Data Analyses
Statistical analyses were performed with Excel 
(Microsoft), Unscrambler (CAMO Software AS), SAS 
(SAS), or MedCalc Statistical Software. We used EasyFit 
to test for rejection of Gaussian (normal) distribution 
by Kolmogorov-Smirnov (K-S) and Anderson-Darling 
(A-D) tests. We used the Excel add-in significance analy-
sis of microarrays (SAM)32 to compare expression using 
the Wilcoxon statistic with 5000 permutations, and the 
Excel add-in Real Statistics Using Excel33 to calculate 
ICCs and Fisher Exact Tests.
Greedy algorithms are extensively used in bioinfor-
matics to solve a variety of  problems. In particular, 
they are well known to be capable of  selecting collec-
tively informative markers from large candidate sets.34 
They linearly build marker selections and avoid brute 
force examination of  all possible subsets of  mark-
ers. In addition, with greedy algorithms weighting of 
individual analytes can be avoided, thus minimizing 
the risk of  overfitting that can occur from techniques 
such as machine learning or statistical modeling that 
develop real-number weights for each analyte to opti-
mize prediction.35
The program first selected the very best single analyte 
for distinguishing the 3 groups. Then a second analyte 
was added that best improved performance, if  possible. 
Additional analytes were selected and added until no fur-
ther selection of any analyte improved performance. The 
chosen set of analytes created an “index” defined as the 
sum of the z scores of selected analytes. In effect, this was 
a weighted sum with all weights being 1; this was possible 
because most of analytes that moderately distinguished 
the 3 groups had higher values in CHR-P than CHR-NP 
and higher values in CHR-NP than UC. Performance 
was defined to be minimization of the sum of the squares 
of the Student’s t test P values for CHR-P vs CHR-NP 
and CHR-P vs UC.
Noting the general principles and pitfalls of classifier 
construction,35–37 classifier analyses on the results of the 
greedy algorithm were executed using 5-by-5-by-5-fold 
cross-validation38–40 with repeated random subsampling, 
implemented in Excel with macros and add-ins. Subjects 
in each group were randomly partitioned into ~20% sub-
groups. Four of the CHR-P, 4 of the CHR-NP, and 4 of 
the UC subgroups were used to train a classifier that was 
tested on the complementary subgroups. There are 125 
possible different combinations of such tests (see supple-
mentary methods). The entire process was repeated 20 
times with 20 initial selections of the random 20% sub-
groups, for a total of 20 × 125 or 2500 executions of the 
greedy algorithm. A review of all the preliminary classifi-
ers easily led to a final, integrated classifier because in the 
125 tests several analytes were repeatedly selected, while 
other analytes were seldom or never selected. To evaluate 
consistency, we also applied a leave-one-out cross-valida-
tion procedure and compared results with those of the 
5-fold cross-validation methods.
The area under the resulting receiver operating curve 
(AUC) assessed the capacity of the index to distinguish 
CHR-P from the other 2 groups using the exact (no 
smoothing) Hand-Till method41 with calculations of SE 
following the methods of Handley-McNeil.42 A receiver 
operating curve (ROC) is a plot of sensitivity (ie, test cor-
rectly predicts true positive declarations/all positives) vs 
the false positive rate (ie, 1 specificity, test correctly pre-
dicts true negative declarations/all negatives). Various 
threshold settings yield the points along the curve.
An AUC of 1.0 indicates perfect classification, and 
for large samples (> 100), an AUC of 0.5 indicates ran-
dom classification. For 30 cases and controls, uniformly 
random numbers yield Hand-Till AUCs averaging 0.54 
(SD = 0.03). Moreover, any classifier method applied to 
real data even after random relabeling of cases and con-
trols can be expected to find weak patterns with AUCs 
> 0.5. This implies the necessity of checking a proposed 
classifier as follows.
Randomly reassigning our raw samples into bins of the 
sizes of the 3 groups and applying the very same classifier 
construction used in true classification should repeatedly 
lead to AUCs smaller than that of true classification. Such 
permutation tests of classifiers have a lengthy history43 and 
are considered powerful techniques of model validation.44
Evaluating Analyte Function
The RBM panel of analytes was chosen because of its 
focus on inflammation, oxidative stress, metabolism, and 
hormonal status, factors consistently associated with 
schizophrenia.9–14 Thus, it is not appropriate to use tools 
that discover “enrichment” of chosen analytes when inter-
preting these results. Instead, we considered it reasonable 
to review the published literature for each selected ana-
lyte to evaluate the function of the analyte, relationships 
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between the analytes (eg, cytokines regulating hypotha-
lamic-pituitary function), and reports of associations with 
schizophrenia or psychosis. We also found overlap with 
previously published reports on plasma analytes that dis-
tinguished persons with schizophrenia using the same mul-
tianalyte platform45–47 (reported in supplements S4 and S5).
Results
Participant Characteristics
Table 1 provides study subject characteristics. All CHR 
subjects met attenuated positive symptom diagnostic 
criteria. The psychosis diagnoses at follow-up of the 32 
CHR-P subjects included 13 with psychosis, not otherwise 
specified, 14 with schizophrenia, 2 with major depression 
with psychotic features, and 1 each with schizoaffective, 
delusional, or bipolar disorder.
Plasma Analytes and Development of Psychosis
Controlling for multiple comparisons, there were no 
analytes that were differentially expressed for CHR-P 
subjects compared with CHR-NP or UC subjects (sup-
plement S6). Comparison of CHR-P with UC subjects 
using permutation analyses with SAM32 assuming a false 
discovery rate of less than 10% identified 18 analytes as 
differentially expressed (supplement S5). We can thus 
expect that of the 18 analytes about 2 are false positives. 
Conducting the same permutation analysis for CHR-P to 
CHR-NP identified only 2 differentially expressed ana-
lytes (supplement S5).
Plasma Analytes and Psychosis Risk Prediction
An analyte could be chosen up to 125 times with each 
of the 20 runs (2500 total executions) in the cross-val-
idation procedure. While somewhat different combina-
tions of analytes were chosen every time, certain analytes 
were frequently chosen (figure 1, supplement S7). Likely, 
the most confidence in the informativeness of analytes 
should attend those most frequently chosen. For exam-
ple, malondialdehyde-modified low-density lipoprotein 
was selected in almost all of the 2500 executions of the 
greedy algorithm. However, after the 15th most popular 
analyte, the frequency fell by 15%, suggesting a cut-off  
point and hence a selection of 15 analytes.
Best practices of classifier development mandate use 
of an external test set that is not used to derive the classi-
fier, with a minimum of 20 subjects in each group.39 The 
number of subjects in this study was too small to set aside 
an external test set, so we applied the 15-analyte index to 
the full data for all 107 subjects (figures 2A and 2B). As 
shown in table 2, using the true data the sum of the most 
frequently chosen 15 analytes gave the highest AUC, 
Fig. 1. Shown analytes were the most frequently appearing in 20 5-by-5-by-5 cross-validation trials, each trial testing 125 partitions to 
generate ~80% subsets of UC, CHR-NP, and CHR-P samples.
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followed closely by AUCs using just the 9 or even 6 most 
frequently chosen analytes.
Classifier methods generally can find patterns in ran-
dom data, but the AUCs of pseudo-classification should 
be weak compared with the AUC of a true classifier of 
true data. Thus, we repeatedly applied exactly the same 
classifier development to pseudo-data obtained by ran-
domly scrambling all the 107 samples into bins of sizes 
35, 40, and 32 (based on the number of subjects in each 
group). As shown in figures 3A and 3B, the AUCs of the 
true classifiers of UC vs CHR-P and CHR-NP vs CHR-P 
were greater than all AUCs of 100 pseudo-classifiers, 
respectively, applied to their pseudo-data. Fitting data 
with beta distributions yielded extrapolations with low P 
values, as shown.
The results of the leave-one-out validation procedure 
were essentially the same as the 5-fold cross-validation 
(supplement S8).
Correlation of 15-Analyte Index With Symptoms
Within the CHR subjects, the 15-analyte index was 
significantly correlated (Pearson) with baseline scores 
from the SOPS for total (r = .26, P = .03) and positive 
(r = .23, P = .05) scales, with trends for disorganized (r = .22, 
P = .07), general (r = .19, P = .10), and negative scales 
(r = .19, P = .11). Specific symptoms from the SOPS with 
strong correlations with the 15-analyte index included 
P1-unusual thought content/delusional ideas (r = .28, 
P = .02), D3-trouble with focus and attention, (r = .25, 
P = .03), G1-sleep disturbance (r = .23, P = .05), and 
G2-dysphoric (depressive, irritable, or anxious) moods (r 
= .24, P = .04). There was no relation between the 15-ana-
lyte index and severity of anxiety symptom as measured 
by the SAS (r = .11, P = .36) or depressive symptoms as 
measured by the CDSS (r = .14, P = .25).
Confounder Analyses
Baseline demographic variables (age, sex, ancestry, SES) 
and time of blood draw did not differ between groups and 
did not confound the relationship of the 15-analyte index 
with group status, nor did baseline measures of anxiety 
or depression or baseline (supplement S9). Given how 
common comorbid depression and anxiety disorders are 
in CHR persons,48 we also evaluated the potential con-
found of current diagnosis with a depression or anxiety 
disorder and found none (supplement S9).
There was no influence of cannabis, nicotine, or alcohol 
use of on the strength of the relationship of the 15-ana-
lyte index to distinguish CHR-P vs CHR-NP or UC sub-
jects, or antipsychotic, or antidepressant drug use with 
the strength of the relationship of the 15-analyte index 
in classifying CHR-P vs CHR-NP subjects. Only 3 UC 
subjects used marijuana or nicotine, only 1 UC subject 
was prescribed antidepressant, and none were prescribed 
antipsychotics, making evaluation of confounding of 
drug use and the 15-analyte index impossible to evaluate 
in CHR-P vs UC comparisons.
Investigation of Analyte Functions
A summary of functions of the 15 analytes included in 
the index is given in supplement S4 together with refer-
ences. From the original panel of immune, hormonal, 
oxidative stress, and metabolism biomarkers, most of 
Table 2. Area Under the Receiver Operating Curve (AUC) Using 
Cut-off  Points Chosen Based On Clustering of Number of Times 
Selected by Greedy Algorithm for Analytes Included in the Blood 
Analyte Classifier
Real Data
CHR-P vs CHR-NP 
AUC (SE)
CHR-P vs UC 
AUC (SE)
Sum best 15 analytes 0.88 (0.043) 0.91 (0.036)
Sum best 9 analytes 0.86 (0.046) 0.87 (0.045)
Sum best 6 analytes 0.83 (0.051) 0.84 (0.048)
Fig. 2. Fifteen-analyte receiver operating curves and 95% confidence intervals: (A) for CHR-P vs UC and (B) CHR-P vs CHR-NP.
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the analytes included in the 15-analyte index are immu-
nomodulatory: as cytokines (interleukin-1B, growth hor-
mone, KIT ligand, interleukin-8, interleukin-7, resistin, 
chemokine [c-c motif] ligand 8) or as proteins involved in 
modulating inflammation including blood-brain barrier 
integrity (matrix metalloproteinase-7, immunoglobulin 
E, and coagulation factor VII). Three of the analytes (thy-
roid stimulating hormone, growth hormone, and cortisol) 
are part of hypothalamic-pituitary axes. Interestingly, 5 
of the included cytokines (interleukin-1B, interleukin-7, 
interleukin-8, KIT ligand, and resistin) are known to 
regulate hypothalamic-pituitary axes. These findings 
indicate some dysregulation of immune-hypothalamic-
pituitary interactions in the emergence of psychosis.
The most frequently chosen analyte, malondialdehyde-
modified low-density lipoprotein, measures a lipoprotein 
damaged by free radicals and is thus a measure of oxi-
dative stress.49 Elevation of apolipoprotein D, found at 
higher levels in CHR-P relative to CHR-NP and UC sub-
jects, is also associated with oxidative stress.50 Oxidative 
stress and inflammation are intricately linked, and both 
are associated with schizophrenia. In summary, the above 
selection of 15 analytes may reflect interacting alterations 
in immune system function, hypothalamic-pituitary func-
tion, and oxidative stress.
Discussion
We report preliminary findings of a blood biomarker 
assay that, if  confirmed, could improve determination 
of psychosis risk in persons experiencing the attenuated 
psychosis risk syndrome. Thus, given a new patient, the 
index value of a blood sample processed for 15 analytes 
as above could be compared with historic data to help 
evaluate likelihood of psychosis. For example, the ROC 
(figure 2B) suggests that if  we accept a sensitivity of ~0.6, 
the index would have a specificity of ~0.9. As applied to 
persons meeting COPS criteria, who have a ~30% risk of 
psychosis in the next 2 years, this yields a PPV of 0.72, 
meaning that 72% of persons identified by the test as at 
high risk are truly at risk, and a negative predictive value 
(NPV) of 0.84, meaning that 84% of persons identified 
by the test as at low risk are truly at low risk of psychosis. 
Persons above this high-risk cut-off  could be considered 
eligible for interventions where the benefits are high but 
the risks/costs may also be high, eg, antipsychotic medi-
cations or relatively intense individual/family therapies. 
Other cut-off  scores could also have clinical utility. For 
example, using a cut-off  score with a sensitivity of ~0.95 
and thus a specificity of ~0.4, yields a PPV of 0.40 and a 
NPV of 0.95; persons scoring below the “high risk” cut-
off  score, but above the lower cut-off  score, might appro-
priately receive brief  counseling and more intense clinical 
monitoring. Thus, this index could provide a framework 
for segmenting the clinical high-risk population along a 
dimension of biological risk and then testing step-wise 
approaches to care.
There are several unique aspects regarding data analy-
sis that warrant comment. Given that the analyte con-
centrations vary 1 000 000-fold, we created a z score for 
each analyte, based on the average and SD of the UC 
subjects. The z score normalization allows the creation 
of an unweighted scale. We propose that the elimina-
tion of weighting minimizes the problem of overfitting 
sometimes encountered with more complex algorithms 
that use various weighting schemes.35 Also, we recognize 
that the relevant patient population will frequently be 
treated with various medications, especially antidepres-
sants and antipsychotics22,51 or used nicotine, marijuana, 
and alcohol, and that such drugs may influence analyte 
levels. Thus, we elected to eliminate analytes that showed 
a possible relation to these substances and furthermore 
Fig. 3. Distribution of AUCs for 100 classifiers built with random data. Shown is a beta distribution fit and P value (A) for UC vs 
CHR-P and (B) CHR-NP vs CHR-P. For UC vs P: the alpha values were >.2 for both Kolmogorov-Smirnov and Anderson-Darling tests 
of fit with beta distributions. Using the top 15, the area under the receiver operating curve (AUC) for true classifier on true data was 0.91. 
For the beta fit, this value is out of range and has a P value = 0. For NP vs P: the alpha values were >.2 for both Kolmogorov-Smirnov 
and Anderson-Darling tests of fit with beta distributions. Using the top 15, the AUC for true classifier on true data was 0.88. For the 
beta fit, this value has a P value = 6.51E-05.
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verified that substance use did not confound relation-
ships with the 15-analyte index. An alternative could be 
to develop different classifiers for persons depending on 
prescription medication treatment, but larger numbers of 
subjects would be required.
A major strength of  this study is the prospective design. 
However, the parent project was not designed around 
plasma biomarker discovery, thus there are several meth-
odological issues that could impact results, causing type 
1 error if  biased and underestimation of  true difference 
(Type II error) if  not biased.52 Relation to meals, physical 
exertion, menstrual cycle, body weight, and presence of 
a cold or allergy were not considered or measured during 
data collection. While all samples were run in duplicate, 
limited resources allowed the analysis of  only one occult 
technical replicate. Finally, with larger samples, normal-
ization could be refined to include sex, age, and other 
factors that could impact analyte expression.45
The results support our initial hypothesis that activa-
tion/dysregulation of  the immune system may play a cen-
tral role in the development of  psychosis. Our findings 
are consistent with the emerging body of  evidence link-
ing inflammation and schizophrenia.14,15 Hypothalamic-
pituitary axis dysregulation is also implicated by our 
results, although we found elevations of  growth and 
thyroid hormones, in contrast to studies in schizophre-
nia subjects that report reductions.53 In support of  the 
involvement of  hypothalamus and pituitary in the onset 
of  psychosis, imaging studies find increases in hypotha-
lamic54 and pituitary55 volumes in persons at elevated risk 
for psychosis compared with unaffected subjects. In addi-
tion, activation of  the hypothalamic-pituitary-adrenal 
axis, as evidenced by elevated salivary cortisol, has also 
been reported in CHR who developed psychosis.11,56,57 
Finally, our finding that elevations in low-density lipo-
protein damaged by oxidative stress predict psychosis is 
in concert with the substantial literature documenting 
oxidative damage in persons with schizophrenia.10
A critical step is testing in other subjects at high risk 
for psychosis, as well as establishing the reproducibil-
ity of  the assay. More work is needed, however, as there 
are likely many other combinations of  analytes with 
utility in psychosis risk prediction, and a blood assay 
could be combined with other clinical, imaging, or elec-
trophysiological measures associated with progression 
to psychosis in clinical high-risk subjects.58 A  better 
understanding of  biomarkers predictive of  psychosis 
could advance our ability to discriminate symptomatic 
persons truly at high risk for psychosis from those with 
minimally elevated risk. If  confirmed, blood biomark-
ers have potential to influence strategies for preventative 
interventions, eg, targeting inflammation, stress reactiv-
ity, or oxidative stress directly. Our results highlight the 
potential promise to identify new targets for prevention 
for psychosis and support the need for further research 
in this area.
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